NURSING MANAGEMENT OF CLIENTS WITH DIABETES. Diabetes Mellitus  A chronic multisystem disease related to abnormal insulin production, impaired insulin.

Slides:



Advertisements
Similar presentations
Oral Hypoglycemic Drugs And Classifications
Advertisements

Diabetes By: Camille Pollio Bianca DeFranco Joann Samosiuk.
DIABETES MELLTIUS Dr. Ayisha Qureshi Assistant Professor MBBS, MPhil.
Type 2 Diabetes Mellitus Aetiology, Pathogenesis, History, and Treatment.
Diabetes Mellitus.
Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins Introduction to Clinical Pharmacology Chapter 42- Antidiabetic Drugs.
Control of Blood Sugar Diabetes Mellitus. Maintaining Glucose Homeostasis Goal is to maintain blood sugar levels between ~ 70 and 110 mg/dL Two hormones.
Oral Medications to Treat Type 2 Diabetes
Diabetes Mellitus Part I
Chapter 36 Agents Used to Treat Hyperglycemia and Hypoglycemia.
Dr Ibrahim Bashaireh, RN, PhD
Diabetes: An Overview Christine Rubie MS, RD, LD.
LONG TERM BENEFITS OF ORAL AGENTS
DIABETES MELLITUS DR. J. PRATHEEBA DEVI. Definition Definition Diabetes is a metabolic disorder characterized by raised levels of glucose in the blood.
What you do this lesson Copy all notes that appear in blue or green Red / White notes are for information and similar notes will be found in your monograph.
Diabetes mellitus.
Adult Medical-Surgical Nursing
Diabetes Mellitus Diabetes Mellitus is a group of metabolic diseases characterized by elevated levels of glucose in blood (hyperglycemia) Diabetes Mellitus.
CARE OF PATIENTS WITH DIABETES MELLITUS JANNA WICKHAM RN MSN LSSC FALL 2013 Chapter 20.
Agents Used to Treat Hyperglycemia and Hypoglycemia
DIABETES AND HYPOGLYCEMIA. What is Diabetes Mellitus? “STARVATION IN A SEA OF PLENTY”
Diabetes Mellitus (Lecture 2). Type 2 DM 90% of diabetics (in USA) Develops gradually may be without obvious symptoms may be detected by routine screening.
Criteria for the diagnosis of DM Symptoms of diabetes plus random blood glucose concentration ≥ 200 mg/dl OR FPG ≥ 126 mg/dl OR Two –hour plasma glucose.
oral hypoglycemic agents
Oral Hypoglycemic Drugs
Sugar. Diabetes Mellitus 20.8 million children and adults in the United States, or 7% of the population, who have diabetes 6.2 million people (or nearly.
Nutrition and Metabolism Negative Feedback System Pancreas: Hormones in Balance Insulin & Glucagon Hormones that affect the level of sugar in the blood.
content sugar glucose Sources Absorption Diabetes Metabolism OF Carbohydrate The control of blood sugar Insulin Diagnosis of Diabetes Sugar level in the.
DIABETES MELLITUS THOMAS MILLIGAN, DO OSU-COM FAMILY MEDICINE.
Diabetes- Chapter 49.
Diabetes Mellitus type 1 Dr. Mahtab Ordooei spring 2015.
Dr. Nathasha Luke.  Define the term glucose homeostasis  Describe how blood glucose levels are maintained in the fasting state and fed state  Describe.
Diabetes- Chapter 43 Revised 11/10. Types of Diabetes Type 1 — insulin- dependent diabetes mellitus (IDDM) Insulin produced in insufficient amount Requires.
Diabetes Mellitus Ch 13 ~ Endocrine System Med Term.
Diabetes Mellitus: Prevention & Treatment Medical surgical in nursing /02/01.
Oral Diabetes Medications Carol Cordy, MD. Goals Understand how type 2 diabetes affects many organs and how this changes over the course of the illness.
Endocrine System KNH 411. Diabetes Mellitus 7% of population; 1/3 undiagnosed $132 billion in health care Sixth leading cause of death Complications of.
"We can be very successful at controlling diabetes."
ADDITIONAL SLIDES FOR ASSIST WITH COMPREHENSION OF LAB CONTENT-MODULE FIVE-DM DENISE TURNER, MS-N.ED, RN, CCRN.
Diabetes mellitus.
Diabetes. Objectives: Diabetes Mellitus (DM) Discuss the prevalence of diabetes in the U.S. Contrast the main types of diabetes. Describe the classic.
Focus on Diabetes Mellitus NUR 171. How insulin works dia2.us.elsevierhealth.com/ondemand/archieAnimations/423.flv.
Dr. Mansour Alzahrani. متى اكتشف داء السكري؟ داء السكري في الحضارة الهندية والصينية القديمة اسهامات علماء المسلمين في داء السكري.
นพ. เฉลิมศักดิ์ สุวิชัย โรงพยาบาล พะเยา. Management of Type 2 Diabetes Mellitus: A New Paradigm Approach Dr. Chalermsak Suwichai Phayao Hospital.
 Insulin is a peptide hormone released by beta cells when glucose concentrations exceed normal levels (70–110 mg/dL).  The effects of insulin on its.
Oral hypoGLYCEMICS.
Diabetes Mellitus Part 1 Kathy Martin DNP, RN, CNE.
What is Diabetes? Definition: A disorder of metabolism where the pancreas produces little or no insulin or the cells do not respond to the insulin produced.
Dr. Sasan Zaeri (PharmD, PhD) Department of Pharmacology, BPUMS.
Focus on Diabetes Mellitus NUR 171. How insulin works.
DIABETES MELLITUS. Diabetes mellitus (DM) is a metabolic disorder resulting from a defect in insulin secretion, insulin action, or both. DM is associated.
Diabetes mellitus.
Dr. Sasan Zaeri (PharmD, PhD) Department of Pharmacology, BPUMS
Diabetes Mellitus Nursing Management.
Diabetes Mellitus Nursing Management.
Interventions for Clients with Diabetes Mellitus
Endocrine System KNH 411.
Drugs for Diabetes Mellitus
Diabetes Jessica Tagerman PharmD
Endocrine System KNH 411.
Diabetes Mellitus Overview
Medical-Surgical Nursing: Concepts & Practice
המשותף לכל סוגי הסוכרת היפרגליקמיה כרונית.
oral hypoglycemic agents
Diabetes.
Endocrine System KNH 411.
Introduction to Clinical Pharmacology Chapter 42- Antidiabetic Drugs
Endocrine System KNH 411.
Endocrine System KNH 411.
Presentation transcript:

NURSING MANAGEMENT OF CLIENTS WITH DIABETES

Diabetes Mellitus  A chronic multisystem disease related to abnormal insulin production, impaired insulin utilization, or both  Affects 25.8 million people  Seventh leading cause of death 

Insult from Diabetes  Leading cause of  adult blindness  End-stage kidney disease  Non-traumatic lower limb amputation  Major contributing factor to  Heart disease  Stroke  Hypertension

Etiology and Pathophysiology  Combination of causative factors  Genetic  Autoimmune  Environmental  Absent/insufficient insulin and/or poor utilization of insulin

Etiology and Pathophysiology  Normal insulin metabolism  Produced by B-cells in islets of Langerhans  Released continuously into bloodstream in small increments with larger amounts released after food  Stabilizes glucose level in range of 70 to 120 mg/dL

Etiology and Pathophysiology  Insulin  Promotes glucose transport in skeletal muscle and adipose tissue  Storage of glucose as glycogen  Inhibits gluconeogenesis  Enhances fat deposition  Increases protein synthesis  Not necessary for glucose transport in brain, liver, blood cells

Etiology and Pathophysiology  Counter-regulatory hormones  Glucagon, epinephrine, growth hormone, cortisol  Oppose effects of insulin  Stimulate glucose production by liver  Decrease movement of glucose into cell  Help maintain normal blood glucose levels

Classes of Diabetes  Type I  Type 2  Gestational  Other specific types

Type 2 Diabetes  Metabolic syndrome increases risk for  Elevated glucose levels  Abdominal obesity  Elevated blood pressure  High levels of triglycerides  Decreased levels of HDLs  Gradual onset  Hyperglycemia may go on for many years  Many times discovered on routine lab testing

Type 1 Versus Type 2 Diabetes

Pre-diabetes  Individuals at risk for type 2 diabetes  Impaired glucose intolerance (IGT)  Two-hour oral glucose tolerance test (OGTT): 140 to 199 mg/dL  Impaired fasting glucose (IFG)  Fasting glucose level: 100 to 125 mg/dL  Asymptomatic but long-term damange already occurring  Patient teaching

Clinical Manifestations  Classic symptoms  Polyuria  Polydipsia  Polyphagia  Weight loss  Weakness  Fatigue  Nonspecific symptoms:  Classic symptoms of type 1 may manifest  Fatigue  Recurrent infection  Recurrent vaginal yeast  Prolonged wound healing  Visual changes Type 1Type 2

Diagnostics 1. Hemoglobin A1C level: 6.5% or higher 2. Fasting plasma glucose level: higher than 126 mg/dL 3. Two-hour plasma glucose level during OGTT: 200 mg/dL (with glucose load of 75 g) 4. Classic symptoms of hyperglycemia with random plasma glucose level of 200 mg/dL or higher 5. Fructosamine 6. Autoantibodies

Collaborative Care  Goals of diabetes management  Decrease symptoms  Promote well-being  Prevent acute complications  Delay onset and progression of long-term complications  Need to maintain blood glucose levels as near to normal as possible

Collaborative Care  Patient teaching  Nutritional therapy  Drug therapy  Exercise  Self-monitoring of blood glucose  Diet, exercise, and weight loss may be sufficient for patients with type 2 diabetes  All patients with type 1 require insulin

Insulin  Exogenous insulin  Insulin from an outside source  Required for type 1 diabetes  Prescribed for patients with type 2 diabetes who cannot control blood glucose by other means

Types of Insulin

Combination Insulin Therapy  Can mix short- or rapid-acting insulin with intermediate- acting insulin in same syringe  Provides mealtime and basal coverage in one injection  Commercially premixed or self-mix

Mixing, Storage, and Administration of Insulin

Mealtime Insulin  Insulin preparations  Rapid-acting (bolus) Lispro, aspart, glulisine Onset of action 15 minutes Injected within 15 minutes of mealtime  Short-acting (bolus) Regular with onset of action 30 to 60 minutes Injected 30 to 45 minutes before meal Onset of action 30 to 60 minutes

Insulin as a Pump  Insulin pump  Continuous subcutaneous infusion  Battery-operated device  Connected to a catheter inserted into subcutaneous tissue in abdominal wall  Program basal and bolus doses that can vary throughout the day  Potential for tight glucose control

Complications of Insulin Use  Problems with insulin therapy  Hypoglycemia  Allergic reaction  Lipodystrophy  Somogyi effect  Rebound effect in which an overdose of insulin causes hypoglycemia  Release of counterregulatory hormones causes rebound hyperglycemia  Dawn phenomenon  Morning hyperglycemia present on awakening  Due to release of counterregulatory hormones in predawn hours

Oral Agents  Work on three defects of type 2 diabetes  Insulin resistance  Decreased insulin production  Increased hepatic glucose production  Can be used in combination

Biguanides  Metformin (Glucophage)  Reduce glucose production by liver  Enhance insulin sensitivity  Improve glucose transport  May cause weight loss  Used in prevention of type 2 diabetes  Withhold if contrast medium is used  Withhold if patient is undergoing surgery or radiologic procedure with contrast medium  Day or two before and at least 48 hours after  Monitor serum creatinine  Contraindications  Renal, liver, cardiac disease  Excessive alcohol intake

Sulfonylureas  ↑ Insulin production from pancreas  Major side effect: hypoglycemia  Examples  Glipizide (Glucotrol)  Glyburide (Micronase, DiaBeta, Glynase)  Glimepiride (Amaryl)

Meglitinides  ↑ Insulin production from pancreas  Rapid onset: ↓ hypoglycemia  Taken 30 minutes to just before each meal  Should not be taken if meal skipped  Examples  Repaglinide (Prandin)  Nateglinide (Starlix)

a-Glucosidase Inhibitors  “ Starch blockers”  Slow down absorption of carbohydrate in small intestine  Take with first bite of each meal  Example  Acarbose (Precose)  Miglitol (Glyset)

Thiazolidinediones  Most effective in those with insulin resistance  Improve insulin sensitivity, transport, and utilization at target tissues  Examples  Pioglitazone (Actos)  Rosiglitazone (Avandia)  Rarely used because of adverse effects

Risk Factors for Diabetic Complications  Hypertension  Genetics  Smoking  Chronic hyperglycemia  Obesity  Poor diet (high fat, high carb)  Sedentary lifestyle

Complications of Diabetes

Chronicity and Diabetes  Damage to blood vessels  CAD, CVD, PVD  Retinopathy Blindness  Nephropathy Renal Failure  Dermopathy  Neuropathy  Infection

Gerontologic Considerations  Increased prevalence and mortality  Glycemic control challenging  Increased hypoglycemic unawareness  Functional limitations  Renal insufficiency  Diet and exercise: main treatment  Patient teaching must be adapted to needs

References  Ignatavicius, D. D. & Workman, M. L. (2010). Medical-surgical nursing: patient-centered collaborative care (6 th ed.). St. Louis, MO: Saunders Elsevier.  Lewis, S. L., Heitkemper, M. M., Dirksen, S. R., & Bucher, L. (2014). Medical-surgical nursing: Assessment & management of client problems (9 th ed.). St. Louis, MO: Mosby  Hogan, M., Dentlinger, N.C., & Ramdin, V. (2014). Medical-surgical: nursing pearson nursing reviews and rationales (3 rd ed.). Boston, MA: Pearson.